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Abstract 
 
 Cystic fibrosis (CF) is a genetic disease which affects about 70,000 patients worldwide, 
and is fatal by age 37 on average, usually due to severe lung infections. Thick mucus builds up in 
the digestive tracts and lungs of CF patients, which causes these respiratory infections as well as 
digestive problems and difficulty breathing.1 Current treatment methods for CF are not optimal, 
as they do not effectively treat the disease and carry excessive risks and side effects. Therapies 
can be improved, however, by using biodegradable, drug-loaded, polymer microparticles as drug 
delivery vehicles.2 These microparticles can be fabricated using electrohydrodynamic co-jetting.3 
 Electrohydrodynamic co-jetting of polymer solutions (jetting, for short) is a method 
developed in the Lahann Lab for fabricating biodegradable, drug-encapsulating, spherical 
microparticles. Jetting allows for control over size, shape, and internal architecture of particles, 
creating many possibilities for unique particle design. During jetting, polymer solutions are 
loaded into two syringes tipped with metal needles and "jetted" onto grounded metal plates. The 
jetting is caused by an electric charge applied to both the needles and the plate. After jetting, 
particles are using SEM (scanning electron microscope) to characterize size and shape 
distributions and confocal scanning laser microscopy (CSLM) to characterize internal 
compartmentalization.3  
 We have found that particles in the 1 micron range can be efficiently, consistently 
fabricated in high yields. This particle size will be optimal for CF treatment because it will allow 
for efficient lung deposition and thus targeted infection treatment.2 These particles can be 
fabricated to allow for release of multiple antibiotics in a controlled, time-dependent manner, 
which will reduce dosing frequency as well as systemic and local toxicity with the aim of 
reducing side effects and improving patient compliance.4 Further, dual antibiotic release will 
enable improved treatment of bacteria, which are often drug resistant. Moreover, particles can be 
surface modified to include targeting and stealth moieties, so as to target the infection while 
evading the immune system.4 
 It is believed that biodegradable, drug-loaded microparticles optimal for CF treatment 
will have a specific set of characteristics and will be widely reproducible.  Here we have worked 
to determine this set of characteristics and produce particles accordingly. We have studied these 
particles' shapes, sizes, inner compartmentalization, degradation and drug release characteristics, 
which have proved to be appropriate for CF therapy. Our future work will include further 
experimentation with release studies, in vitro and in vivo works. 
 
  
 
 
  
Introduction 
 
1.1 Introduction to cystic fibrosis disease 
 
 Cystic fibrosis (CF) is an inherited, recessive and autosomal disease which affects about 
one in 2,000 newborns in Caucasian populations. The disease does, however, affect all ethnic 
groups. Approximately 70,000 patients worldwide are affected by CF, and the average lifespan 
of a CF patient is 37 years. CF primarily effects the respiratory system, and severe respiratory 
infections are the primary cause of death in CF patients. However, this multi-functional disease 
also effects the pancreas and liver, gastrointestinal tract and reproductive system, and the sweat 
glands. Symptoms of CF vary by person, but the main symptoms of the disease include difficulty 
breathing, continuous coughing (usually expelling mucus), wheezing, decreased ability to 
exercise, intestinal blockage, severe constipation, poor weight gain and growth, and severe, 
sometimes fatal, lung infections. 2 Here, we focus on understanding and treating bacterial 
infections in the respiratory tract, since these are the primary cause of death in CF patients and 
are seen in nearly all CF patients. 2   
 CF is caused by mutation of the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene on chromosome 7. There are more than 800 known mutations that can cause the 
disease, the most common mutation being a deletion of phenylalanine in position 508 in the 
amino acid sequence. 2 Mutations in the CFTR gene lead to malfunction of the CFTR protein, 
which is responsible for regulating ion and water movement across the epithelium. The 
mutations result in defective chloride ion channels, leading to decreased chloride secretion into 
the airways. This then causes increased sodium absorption from the airways due to the disrupted 
ion concentration gradient. This causes the airway mucus to become dehydrated, and the volume 
of the airway surface liquid (ASL) decreases, leading to the accumulation of purulent secretions 
and impaired mucociliary clearance (MCC). Mucociliary clearance is the complex process by 
which the cilia lining the airways works to clear airway secretions so that they can be 
expectorated or swallowed. It is an important defense mechanism against infection. Without 
strong mucociliary clearance, CF patients are prone to frequent, severe lung infections, which 
can be fatal. Their inefficient MCC leads to buildup of thick mucus builds lungs which causes 
these respiratory infections in addition to difficulty breathing.2  
 We seek to fabricate drug delivery vehicles which can navigate this complex environment 
created by the reduction of ASL and of MCC function, in order to deliver antibiotics efficiently 
to the sites of infection in the lungs, thus reducing side effects and dosing frequency, and 
improving efficacy. We hypothesize that this can be done by electrohydrodynamic co-jetting of 
polyanhydride microparticles containing the commonly used antibiotic Azithromycin in one 
compartment, and the experimental antibiotic carboxy-TEMPO in the other compartment. The 
use of two antibiotics will improve the chances of killing drug resistant bacteria, which occur 
frequently in respiratory infections and are the implicated severe, long-lasting, difficult-to-treat 
disease. 
 Both Azithromycin and carboxy-TEMPO target Pseudomonas aeruginosa, in addition to 
other bacteria. This makes them powerful for CF treatment, since Pseudomonas is the primary 
bacteria that infects the lungs of adult CF patients. It is found in 54.4% of CF patients overall, 
and it is found in 80% of the patients by age 18. While other pathogens contribute to morbidity 
and mortality as well, such as such as Burkholderia spp., Achromobacter spp. and 
Stenotrophomonas maltophilia, the high incidence of P.aeruginosa in adults makes it an 
important pathogen to note. 5, 6, 7 
 We have chosen the drug Azithromycin because it is currently, commonly used to treat 
CF. It is a particularly useful drug for this disease due to its anti-inflammatory properties in 
addition to its antibiotic activity. Azithromycin is a 15-membered ring which is stable at acidic 
pH, important for treating infection in CF biofilms which usually have a pH of approximately 
5.6. Azithromycin is a macrolide antibiotic in the azalide class. It inhibits protein synthesis in 
bacteria by binding to the 50S ribosomal subunit of the bacterial 70S ribosome. This deactivates 
the ribosome by inhibiting peptidyl transferase activity and interfering with amino acid 
translocation during translation. Thus, the bacteria can no longer effectively make protein, and so 
it dies. Another benefit of using Azithromycin is that it has a long half life, which helps to reduce 
dosing frequency and administration lengths.5 
 We have chosen to complement with carboxy-TEMPO due to the promise shown by this 
drug and similar members of the nitroxide family as a drugs for CF. Nitroxide antibiotics have 
been shown to disperse biofilms, but have yet to gain complete FDA approval. The nitroxide 
drug was originally used, but later we decided to complement with Azithromycin due to the 
greater certainty in its effects in CF patients.6  
 
1.2 Current treatment methods for Cystic Fibrosis 
  
 Many current treatment methods lack effectiveness and are accompanied by harmful side 
effects.1 This is due in part to intravenous drug administration, which does not target infected 
areas and thus provides increased systemic exposure.2 For example, antibiotics kill harmful 
bacteria in the lungs, but may also kill important bacteria in other areas of the body. Drugs 
administered via inhalation are likely to have fewer side effects and to be more effective because 
they are administered directly to the site of mucus buildup and infection in the lungs.2  
 Modern molecular drug delivery vehicles can also administer drugs more efficiently to 
infection sites with fewer side effects. Using these vehicles, and the inhalation route, better 
treatments can be achieved.2 There are many molecular drug delivery vehicles currently being 
researched which could be taken via inhalation, including liposomes, polymeric micelles, and 
drug polymer conjugates.2 These vehicles are also not optimal, however, because they do not 
have the multiple functionalities necessary to optimally treat CF, such as the ability to deliver 
multiple drugs simultaneously, or to chemically target the sites of infection. Additionally, they 
are not optimized to evade the immune system, or to provide sustained and controlled drug 
release.2 While the current treatment options for CF are not optimal, therapies can be improved 
using polymer microparticles as drug delivery vehicles.2 
 
1.3 Drug Loaded Polymer Microparticles as Drug Delivery Vehicles   
  
 Biodegradable, drug-loaded, polymer microparticles are more advanced drug delivery 
vehicles, which can be optimized to chemically target infection sites, deliver multiple drugs 
simultaneously with different controlled release profiles, and evade the immune system.3 
Currently, the optimization of an efficient method for fabricating particles with these capabilities 
is an important goal in the field.4 Electrohydrodynamic co-jetting of poly(lactide-co-glycolide) 
polymer solutions (jetting) is a method developed in the Lahann Lab for fabricating such 
microparticles.8 Jetting allows for control over size, shape, and internal architecture of particles, 
creating many possibilities for unique particle design.8 Particles with multiple compartments can 
be produced, allowing a single particle to deliver multiple drugs, with multiple, distinct release 
kinetics.8 For CF treatment, this will allow antibiotics, mucus dispersal agents, and anti-
inflammatory drugs to be delivered simultaneously over controlled periods of time, which will 
reduce dosing frequency as well as systemic and local toxicity with the aim of reducing side 
effects and improving patient compliance.4 Further, particles can be surface modified to include 
targeting and stealth moieties, so as to target the infection while evading the immune system.4  
 Further, all of these goals can be better achieved by using the inhalation delivery route. 
Particles will be inhaled by patients as an aerosol. This method has been used before for 
pulmonary drug delivery, and has shown promise for many reasons. This is a simple, non-
invasive delivery route, which improves patient comfort as well as compliance. This method also 
caters to the properties of the lung: the large epithelial surface area, the high vascularization, the 
thin alveolar epithelium, a relatively low enzymatic activity compared to the gastrointestinal (GI) 
tract and no first pass effect all make drug delivery via inhalation more effective. The first three 
characteristics provide improved conditions for drug absorption and thus efficient action. The 
lower enzymatic concentration prevents drugs from being degraded quickly, as they would be in 
the GI tract. And lastly, without the first pass effect, i.e. without having to circulate the body 
before finding its target, and thus risking degradation, toxicity, and/or removal from the system, 
the drug can be far more effective and less toxic to the body.  There are, of course, caveats to 
pulmonary delivery as well, such as difficulty in determining an effective way to administer the 
drug as an aerosol, and concern of hindrance of drug transport into the lungs by metabolic 
enzymes or efflux pumps. However, these concerns are mitigated in part by delivering the drug 
in surface-modified, biodegradable polymeric microparticles, which will be more simply 
aerosolized, and can be optimized to evade some of the biochemical hindrances to lung entrance.  
 It is difficult to jet multi-compartmental particles with the correct size, shape, drug 
compartmentalization, and release profiles. For example, drug/polymer solubility in jetting 
solutions is an obstacle, as there are limited solvent and polymer options that meet 
biocompatibility constraints while maintaining dielectric properties optimal for jetting. Addition 
of drug to jetting solutions can have severe effects on jetting, due to changes in dielectric 
constant and potential salt formation. Variable humidity alters jetting results by changing the 
dielectric constant of the air and thus the electric field between the plates and needles, making it 
difficult to produce optimal particles consistently. Importantly, production of CF drug delivery 
particles via jetting has not been studied before, so there is little base knowledge on expected 
outcomes. However, these challenges can be overcome with extensive optimization of the jetting 
process. 
 The polymer I am using is Polysebacic Acid, a biodegradable, FDA-approved 
polyanhydride. This polymer was chosen due to its biocompatibility, government approval, 
degradation characteristics, and ability to be jetted with. The solvent used includes both 
chloroform and dimethyl formamide (DMF), in concentration ratios ranging between 95:5 and 
50:50 chloroform: DMF. These are common jetting solvents and ratios, which are optimized for 
each case to meet necessary solubility constraints while yielding particles of ideal size and shape.  
 Particle size and shape can be controlled by varying several jetting parameters, including 
flow rate (how fast solutions are pumped out of solutions; usually ranges from 0.1-0.4 mL for 
particle jetting), distance from needles to plate, polymer concentration, solvent ratio, drug 
concentration, additive concentration (liquid or solid chemical additives may be used), needle 
gage, and humidity. These parameters must thus be optimized in order to fabricate ideally size 
and shaped particles in high yields.  
 
1.4 Overview: Hypothesis and Plan of Action   
 
 In order to develop a consistent protocol for fabricating particles optimal for CF drug 
delivery, I jetted particles with different drug and polymer concentrations, solvent ratios, and 
flow rates. Ideal particles will be 1-5 micron diameter spheres, as this will allow for efficient 
lung deposition and thus targeted infection treatment.2 In the past, larger particles have been 
jetted using dimethylformamide (DMF) as the primary solvent, while for smaller particles, 
chloroform has been used. This is the case since DMF has a higher dielectric constant than 
chloroform. Therefore I hypothesized that by varying the ratio of chloroform: DMF as jetting 
solvent, I would be able to control particle size. I also hypothesized that by varying polymer 
concentration and solution flow rate I could control particle size and shape distributions, since it 
has been seen that higher polymer concentrations and slower flow rates yield larger particles, up 
to a limit at which fibers are produced.4  
 I characterized the particles I jetted in order to determine which formulation was optimal, 
using methods such as Scanning Electron Microscopy (SEM) to determine shape and size 
distribution and Confocal Laser Scanning Microscopy (CLSM) to determine internal 
compartmentalization.3 Once an optimal formulation was determined, I performed degradation 
and release studies to quantify particle degradation characteristics and drug release profiles. 
Degradation can be qualitatively observed using SEM and quantified using ImageJ software (to 
measure particle diameter change over time). Drug release (mg drug released per time) can be 
quantitatively monitored using UV-visible spectrophotometry and a calibration curve for 
strongly absorbent drugs, and High Performance Liquid Chromatography (HPLC) otherwise. 
The Lahann Lab, in Germany and in Ann Arbor, provided me with all of the resources necessary 
to complete these studies. 
 
Materials and Methods 
 
2.1 Materials 
 
Chloroform, dimethylformamide (DMF), phosphate buffered saline (PBS), Tween 20, the 
polyanhydride Polysebacic Acid (PSA), carboxy-TEMPO, Azithromycin, the fluorescence dye 
poly[(m-phenyl-enevinylene)-alt-(2,5-dibutoxy-p-phenylenevinylene)] (MEHPPV) and the 
fluorescence dye poly[tris(2,5-bis(hexyloxy)-1,4-henylenevinylene)-alt-(1,3- 
phenylenevinylene)] (PTDPV)  as the blue and green markers, respectively, for confocal imaging 
were used as purchased from Sigma Aldrich, USA. Polylactide-co-glycolide (PLGA) 5002A was 
purchased from Lakeshore Biomaterials.  
 
2.2 Particle Fabrication 
 
 Microparticles were fabricated using the electrohydrodynamic cojetting procedure, a 
schematic of which is shown in Fig. 1. Briefly, polymer solutions were dissolved separately and 
loaded into separate 1 mL syringes which were held together by a syringe holder. The syringes 
were tipped with metal needles whose tips were held together in a thin plastic sleeve, forming a 
parallel dual capillary system. Using a syringe pump, the solutions were expelled at flow rates of 
0.4 mL/hr.  The cathode of a high voltage source was attached to the needles, and the anode was 
attached to the collecting substrate, a grounded metal plate. A large electric field was applied to 
the needles, causing formation of a Taylor cone and thus an electrified polymer jet.  All jetting 
experiments were performed under ambient conditions.8 
 
 Fig. 1. Jetting Schematic. Solutions composed of polymer and 
(drug) are slowly pumped out of metal needles onto a grounded 
metal plate, forming a Taylor cone and yielding a thin layer of 
particles deposited on the plate.  
 
 A needle to-substrate distance of 30 cm was maintained 
throughout all experiments. A metal sheet acted as the counter 
electrode, onto which the microparticles were deposited and 
then collected for further processing. The jetted microparticles 
were imaged via CLSM (Confocal Laser Scanning Microscopy) using an Olympus Confocal 
Microscope, and an Amray SEM (Scanning Electron Microscopy), at the Microscopy & Imaging 
Laboratory facilities at the University of Michigan in Ann Arbor, MI, USA and the imaging 
cores at the Karlsruhe Institute for Technology (KIT) in Karlsruhe, Germany. Microparticle and 
nanoparticle diameter measurements were done using Image-J software. 200 particles were 
counted per image. 
 
2.2.1 Fabrication of non-drug-loaded PSA microparticles (control) 
 
 Particles were fabricated with both compartments containing Poly Sebacic Acid (PSA) 
20% w/v, and one compartment containing green dye; the other, blue dye. Two solvent ratios 
were used: the first was 95:5 Chloroform: Dimethyl Formamide (CHCl3: DMF) and the flow rate 
was 0.4 mL/hr. After analysis with ImageJ, the average diameter was 4.84 μm (100 particles 
measured), with a range of 2.8-7.1 μm. Images are included in Fig. 2, A. The second solvent 
ratio was 50:50 chloroform: DMF, seen in figure 15. ImageJ analysis will be performed as part 
of our future work. In order to dissolve jetting solutions with PSA, the polymer must be 
dissolved in DMF before adding chloroform, due to low PSA solubility in chloroform. First, 
solutions containing PSA and DMF must be bath sonicated for approximately 1 hour, then once 
chloroform is added, solutions must be bath sonicated for 1-3 hours, until solutions become 
clear. 
   
2.2.2 Fabrication of carboxy-TEMPO encapsulating PSA microparticles 
  
 For particles containing solely carboxy-TEMPO in both compartments, all jetting 
solvents for the particles discussed in this section contain 2% v/v Triethyl amine (TEA) as 
additive in a 95:5 CHCl3: DMF solvent ratio. All particles discussed in this section were jetted at 
a flow rate of 0.4 mL/hr, unless otherwise noted. 
 It is notable that jetting solutions containing both Carboxy-TEMPO and PSA are difficult 
to dissolve, and the following steps must be taken in order to successfully dissolve such 
solutions: 
 
 1. A stock solution of Carboxy-TEMPO must be dissolved in DMF+TEA, so that for 
each solution made, (half the amount DMF needed) + (20 uL TEA per 1 mL jetting solution) + 
(the full amount of Carboxy-TEMPO needed) can be pipetted into the complete jetting solution. 
For example, for a 1 mL jetting solution with 5% w/w loading of the drug, 25 uL DMF+20 uL 
TEA+0.01g Carboxy-TEMPO would be added to the complete jetting solution in order to 
achieve 50 uL of DMF total (5%). 
 This would use the drug loading calculation ([Drug] / [Polymer]) x 100=X% loading. 
Alternatively, the calculation (([D]/ ([D] + [P]))*100 = X% loading, could be used. P is the 
polymer, which is used at 20% w/v (or for a 1 ml solution, 0.2 g), and D is the drug. 
 This solution is then vortexed and then bath sonicated for 1 hour. 
 
 2. All of the PSA needed for the jetting solution (20% w/v) is then dissolved in half the 
amount of DMF needed for the solution (i.e. for 1 mL, 25 uL DMF is used). This solution is then 
vortexed and then bath sonicated for 30 min. 
 
 3. The Carboxy-TEMPO stock is at this point dissolved, and is mixed with the PSA 
solution, resulting in the full amount of DMF + TEA + Carboxy-TEMPO + PSA needed for the 
jetting solution. This solution is then vortexed and then bath sonicated for 25 min. 
 
 4. The full amount of CHCl3, i.e. 950 uL per 1 mL solution (95% v/v), is then added to 
the solution, vortexed, then bath sonicated until clear, for approximately 2-3 hours. 
 5. Solutions are then ready to jet. Jetting is done at 0.4 mL/hr, and plates are changed 
every 20 min, thus depositing 0.133 mL of solution onto each plate. 
 
 Particles were fabricated with both sides containing Poly Sebacic Acid (PSA) 20% w/v 
and 5% carboxy-TEMPO w/w, and one side containing green dye, while the other side contained 
no dyes. The solvent was 95:5 CHCl3: DMF and the flow rate was 0.4 mL/hr. After analysis with 
ImageJ, the average diameter was 1.96 μm, with a standard deviation of 0.642 and a range of 
0.9-3.7 μm. Images are seen in Fig. 2, B.  
 Two additional sets of particles were jetted using the same parameters, with the exception 
that one set contained 2.5% carboxy-TEMPO w/w, and the other contained 10% carboxy-
TEMPO w/w. The jetting for the 10% drug-loaded particles was ineffective, most likely due to 
the strong change in dielectric constant of the solution due to high drug concentration. The 
jetting of particles with 2.5% drug loading was effective, and particles yielded had an average 
diameter of 2.19 μm, and a standard deviation of 0.637, with a range of 1-3.5 μm. 2.5% drug-
loaded particles are seen in Fig. 2, C. 
 Two additional sets of biphasic particles were jetted, with different compositions of each 
compartment. First, particles were jetted with one side containing only PSA 20% w/v, and the 
other side containing PSA 20% w/v and carboxy-TEMPO 5% w/w. After analysis with ImageJ, 
the average diameter was 2.06, with a standard deviation of 0.693 and a range of 0.9-3.5 μm. 
Images are included in Fig. 2, D. Second, particles were jetted with one side containing PLGA 
5004A 10% w/v, and the other side containing PSA 9% w/v and carboxy-TEMPO 5% w/w. 
ImageJ analysis showed an average diameter of 3.37 μm, with a standard deviation of 1.19, and a 
range of 0.7-5.2 μm. Images are shown in Fig 2, E. 
 For particles containing carboxy-TEMPO in only one compartment, carboxy-TEMPO 
was simply dissolved in the green-dyed chloroform solution before adding to the PSA+DMF 
solution.  
 
 
2.2.3. Fabrication of Azithromycin encapsulating PSA microparticles 
 
Particles were fabricated with both compartments containing Poly Sebacic Acid (PSA) 
20% w/v, and one compartment containing green dye; the other, blue dye. The solvent ratio used 
was 95:5 Chloroform: Dimethyl Formamide (CHCl3: DMF) and the flow rate was 0.4 mL/hr. 
One compartment was loaded with 5% Azithromycin, which was simply dissolved in the 
chloroform solution, which also contained blue dye, before jetting. Images of Azithromycin-
encapsulating particles are seen in figures 13, 14 and 16. 
 
2.2.4 Fabrication of Azithromycin and carboxy-TEMPO encapsulating PSA microparticles 
 
Particles were fabricated with both compartments containing Poly Sebacic Acid (PSA) 
20% w/v, and one compartment containing green dye; the other, blue dye. The solvent ratio used 
was 50:50 Chloroform: Dimethyl Formamide (CHCl3: DMF) and the flow rate was 0.4 mL/hr. 
One compartment was loaded with 5% Azithromycin, which was dissolved in the chloroform 
solution, which also contained blue dye, before jetting. The other side was loaded with 5% 
carboxy-TEMPO, which was dissolved in the chloroform solution containing green dye, before 
jetting. Images are seen in Figure 17. 
 
2.3 Degradation Studies 
 
In order to determine degradation characteristics of the microparticles containing 20% PSA w/v 
and 5% w/w carboxy-TEMPO, as well as microparticles containing only 20% PSA w/v, I used 
the following protocol. 
 
Degradation study protocol 
 
1. Collect 1 mg particles dry, using a plastic razor blade to scrape particles off of collecting 
substrates.  
2. Place particles in a 2 mL centrifuge tube and add 1 mL Phosphate Buffered Saline solution 
(PBS) or pH 5 buffer +1% tween. 
3. Leave this particle suspension on a shaker for various time periods of interest both at room 
temp and at 37C.  
The time periods I chose were 15 min, 30 min, 60 min, 5 hr, 24 hr, 48 hr, and 5 days.   
4. After the desired time period has elapsed, centrifuge the sample at 15000 rpm for 2 min.  
5. Wash with deionized water 5 times.  
6. Tip sonicate under the following parameters: 30 sec total, 1 sec on, 5 sec off, 20 amp. Sonicate 
with the solution on ice to avoid melting the particles.  
7. Pipette 10 μL of the solution onto a silica wafer and image using SEM.  
 
2.4 Carboxy-TEMPO Release Study Protocol 
 
 It is worth noting that the absorbance of carboxy-TEMPO is not very high (my 
calibration curve linear equation is 4.7x, while the Ann Arbor lab normally works with dyes they 
are about either 44 or 200x). This must be taken into account when determining the necessary 
concentration of drug loaded in my particles, and the amount of particles needed to do the release 
study.  
 The following release study protocol was developed: 
(I) Calculating concentration of particles needed:   
 1. Set 0.001 as the lowest bar for 5%. This means at a minimum, it will be possible to get 
a reading for a 5% release of material. 0.001 is chosen because this is the lowest value at which 
the UV visible absorbance measurement can be consistently, accurately taken by a typical plate 
reader. Based on the specific plate reader in use, this amount may need to be varied. 
 Note: In this particular study, 0.001 absorbance is 0.00021 mg/ml concentration.  
 2. Based on this amount, calculate the 100% amount of the drug needed. In this case, that 
is 0.004197 mg/ml. 
 3. Use a total volume of 40 mL, and calculate the total amount of drug needed. In this 
case, that is 0.1678 mg. 
 4. For an X% loading of drug in the particles, calculate the mass of particles required. In 
this case, for 5% loading, 3.36 mg of particles are needed. It is possible to use a higher mass, but 
using a lower mass will not allow a detectable signal for 5% drug release, and this is suboptimal.  
Take release measurements in triplicate, but prepare four samples, in case one sample becomes 
damaged. In this release study, 5 samples were used, each with 7 mg of particles, as this was the 
maximum amount of particles available. 
Release study: 
 1. Measure out the particles in small centrifuge tube and add a 2 mL solution of PBS and 
1% tween. Disperse the particles gently. Do not use sonication or other harsh methods of 
dispersion, as this can cause the drug to release. 
 2. Rinse dialysis tubes with DI H2O. Prepare one tube for each release sample. Fill the 
tubes with DI H2O (inside and outside the tubing) and let stand for about 15-30 min before use.  
 3. Pour each 2 mL suspension of particles in PBS+1% tween and into a dialysis tube.  
 4. Rinse the small centrifuge tube again with 2 ml of PBS+1% tween and pour that into 
the dialysis tube again. Rinse again with 1 mL, in order to make sure that all of the particles are 
out of the small centrifuge tube and into the dialysis tube. Total volume will now be 5 mL.  
 It is important not to add the particles dry to the dialysis tube, because then it is possible 
for them to start off in aggregates, which will alter their release properties due to the blocking of 
the solvent from reaching all sides of each particle.  
 5. Fill 50 mL tubes with 35 mL of PBS + 1% tween and put the dialysis membranes in 
them. Put them on a shaker and incubate at 37 degrees Celsius. Take absorbance readings at 3 hr, 
a 5 hr, a 7 hr, and 24 hrs time periods, and if the release is still very rapid at 24 hrs, take a 
reading at 30 hr as well.  Then take readings every 24 hrs until a plateau is reached. It is also 
possible to take time points in between so long as they are consistent. 
 6. Take absorbance readings for the fluid outside the membrane using a 96 well plate 
with 200 uL per well. If values are close to 0.005, take readings at longer time intervals (e.g. 24 
hours vs. 12 hours).   
For drug loading calculations:  
((D/ (D+P))*100 = X%, where D is the Drug concentration and P is the Polymer concentration, 
which is 20% in this case.  
 
Results and Discussion  
 
3.1 Particle Fabrication 
 Using the methodology described in prior sections, several sets of particles were jetted in 
order to test the effects of drug concentration on particle size and shape, and to determine the 
viability of jetting particles with various drug concentrations, in addition to the viability of 
jetting particles with different compartmentalization schemes and different polymers. Here I 
confirm the versatility of particles that the jetting method can produce, and I show that this 
versatility indeed applies to this specific project. The ability to fabricate particles with different 
properties opens up the utility of the technique developed here to apply to different drug delivery 
strategies for CF, and shows that other unique formulations needed for future CF and other 
antibiotic delivery applications are likely to be possible once optimized. Scanning Electron 
images of five different particle formulations are shown below. 
 
 
Fig. 2. Scanning Electron Microscope images showing particle size, shape, and surface 
morphology. A) Control- Poly Sebacic Acid 20% w/v. B) Poly Sebacic Acid 20% w/v, 2.5% 
drug loading, C) Poly Sebacic Acid 20% w/v, 5% drug loading, D) Poly Sebacic Acid 20% w/v, 
5% drug loading in one compartment, no drug in the other, E) Poly Sebacic Acid 9% w/v in one 
side, PLGA 5004A 10% w/v in the other, 5% drug loading in both sides.  All scale bars are 10 
μm. 
  There is a significant change in particle size when jetting empty particles as compared to 
drug-loaded particles. In order to determine if this size change is due to the addition of the drug, 
or the addition of the TEA as additive to help dissolve the drug, I jetted empty PSA particles 
with TEA as additive for comparison: the particles contained PSA 20% w/v, 95:5 CHCl3, and 
2% v/v TEA as additive. Jetting did not yield particles, so a comparison could not be drawn. 
Future work could be done to determine effects on particle size with variable TEA concentration. 
However, to maintain jetting which yields particles (as opposed to amorphous, thin shapes), TEA 
concentration cannot be raised past about 2% of the jetting solution, so these experiments would 
be difficult to conduct, since varying the TEA concentration within the window of 0-2% would 
likely not yield a significant size difference. 
 
3.2 Degradation Study Results for carboxy-TEMPO particles 
 
Images of degradation studies are included in Figs. 3-7. Several different setups are shown to 
allow for different comparisons to be drawn. 
 
Fig. 3. Degradation studies at 37C for short time periods. Images taken using Scanning Electron 
Microscopy. Comparisons are shown between pH 5 and pH 7 degradation, for particles with and 
without drug loading.  
 
Fig. 4. Degradation studies at 37C for long time periods. Images taken using Scanning Electron 
Microscopy. Comparisons are shown between pH 5 and pH 7 degradation, for particles with and 
without drug loading.  
 
 
 
Fig. 5. Degradation studies at room temperature for short time periods. Images taken using 
Scanning Electron Microscopy. Comparisons are shown between pH 5 and pH 7 degradation, for 
particles with and without drug loading.  
 
 
Fig. 6. Degradation studies at room temperature for long time periods. Images taken using 
Scanning Electron Microscopy. Comparisons are shown between pH 5 and pH 7 degradation, for 
particles with and without drug loading 
 
The degradation of particles containing PLGA in one compartment was studied as well, using the 
same protocol with the exception of the use of different time periods. Results are shown in Fig. 
7, as compared to empty PSA particles and drug-loaded PSA particles.  
 
 
 
Fig. 7. Degradation of PSA particles with and without drug loading as compared to particles with 
different drug loading and different polymers in each compartment. All images taken after 5 days 
of incubation at 37C. 
 
 Correlation between degradation, pH, and temperature is somewhat unclear. Future 
experimentation studying drug release with additional monitoring experiments, such as High 
Performance Liquid Chromatography (HPLC), will be conducted in order to better elucidate if 
the particles do indeed degrade faster and release more drug sooner at higher pH, which would 
be optimal for CF drug delivery due to the lower pH biofilm microenvironment. This would 
allow for drug release at primarily the site of infection, reducing toxicity and improving efficacy. 
 
3.3 Polymer degradation prior to jetting 
 
 In order to determine if the polymer was degraded prior to jetting, an IR spectrum was 
taken for a container of PSA which had been opened two days beforehand and stored under 
vacuum. The following spectrum in Fig. 8 was generated. 
 
Fig. 8. IR spectrum of newly opened PSA, with annotated peaks. Degradation is visible due to a 
notable carbonyl peak near 1700 cm-1. However, degradation is not extreme, since there are still 
peaks characteristic of non-degraded PSA visible. In completely degraded PSA, these peaks are 
overpowered by the carbonyl peak.  
 
 The Lahann Lab in Ann Arbor lab also took an IR spectrum with PSA used there. IR 
spectra of PSA stored in room conditions for greater than one month showed extreme 
degradation (carbonyl peak at 1700 entirely overpowered peaks near 1000 and 1600). IR spectra 
of newly opened PSA showed partial degradation. Sigma Aldrich was contacted regarding the 
issue, and they confirmed that the polymer is partially degraded upon packaging and sale. 
Resolution and receipt of non-degraded polymer has yet to occur.  
  
3.4 Release studies 
 
 Despite partial polymer degradation prior to jetting, a preliminary release study was run 
in order to determine if the protocol methodology is effective.  
 The carboxy-TEMPO has a UV absorbance peak 245 nm, so a calibration curve was 
made in order to allow for UV absorbance to quantify drug release. The absorbance curve of the 
carboxy-TEMPO is shown in Fig. 9, and the calibration curve in Fig. 10. 
 
This carbonyl 
peak indicates 
partial 
degradation of 
the polymer 
These peaks are still visible 
however, so the degradation 
is not extreme 
 
Fig. 9. Absorbance spectra for carboxy-TEMPO at different concentrations. 
 
  
 
Fig. 10. Calibration curve for carboxy-TEMPO in PBS+0.01% Tween20. 
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 In Fig. 11, a preliminary release curve is shown, which was generated using the protocol 
described previously. Concentrations of carboxy-TEMPO were calculated based on the 
calibration curve in Fig. 10 above.  
 
 
Fig. 11. Carboxy-TEMPO Release from PSA Microparticles over 120 hours. 
 This release curve takes on an unexpected shape. Typically, with PSA microparticles 
fabricated using the jetting method, there is an initial burst release followed by a levelling off 
of the curve within 48 hours. It is important to note: between 0 and 3 hours, for part of this 
time, the incubation temperature was 60 degrees C, because someone changed the 
temperature setting of the machine where I had left my samples (even though I left a note 
saying not to do that). So this has probably effected the results.  
 Another important concern is that the absorbance values are much higher than expected: 
for example, the absorbance at 245 nm is 0.091 for the 48 hour sample, indicating a 
theoretical carboxy-TEMPO concentration of 0.19 mg/mL. The total amount of drug in the 
particles (7 mg particles with 4.76% loading) is 0.33 mg, in 40 mL. This means that for 
100% drug release, there would be a concentration of 0.0083 mg/mL. Therefore, the data 
show absorbance values that indicate greater than 100% release. This may indicate the 
presence a contaminating substance with an absorbance in solution, a malfunction of the 
machine, or a problem of a different nature. 
 In order to resolve this issue, the shape of the spectra for the 48 hour sample was more 
closely analyzed. As seen in Fig. 12, the absorbance spectrum for the 48 hour release sample 
has a noticeable shoulder, which most likely indicates the presence of a contaminating 
substance with an absorbance in solution. 
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Fig. 12. Left: Spectra for the 48 hour release sample shows a significant shoulder as compared to 
Right: the pure carboxy-TEMPO calibration spectra, which show a smooth curves. In B, the 
colors of the lines correspond to amounts of carboxy-TEMPO in solution in mg/mL.  
 Several possible hypotheses have been considered to account for what could be occurring 
to cause these usual release results. It would have been possible that the release media (PBS + 
tween) could have been contaminated, but this hypothesis is refuted because the blank would 
have accounted for this. It is possible that release membranes were contaminated despite rinsing, 
but this is unlikely. Another possibility is that the dyes within the particles could have partially 
degraded at very high temperatures (e.g. the brief 60C stint) and yielded absorbent fragments 
which escaped the release membranes. The full length dyes would be too long to escape the 
membranes, as would the full length PSA, but it is also possible that the PSA degraded at 60C 
and the degraded polymer structure escaped the membrane. However, this structure would 
almost certainly not have an absorbance, so this is unlikely. It is possible that contamination 
occurred during collection of particles, though this would likely have become apparent before 48 
hours of release experiments had elapsed. 
 It would be best to resolve this issue before the next release study is done, but as this has 
proved difficult, the best option seems to be to just try again. Of course there is always the 
chance of incorrect calculations, calibration, plate preparation, et cetera, and repeating the 
experiments carefully would ideally eliminate these types of error. Thus, future work will 
include another release study, performed with the greatest attention to detail.  
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3.5 Jetting in Germany as compared to jetting in Michigan 
 In order to determine if jetting done in the Lahann lab in Karlsruhe, Germany could be 
reproducible with significant accuracy in the Lahann Lab in Ann Arbor, MI, jetting of particles 
with 5% loading of carboxy-TEMPO, 20% w/v PSA, 95:5 CHCl3: DMF solvent ratio, with 2% 
TEA as additive, and a flow rate of 0.4 mL/hr were jetted in the Ann Arbor lab. Particles jetted in 
Ann Arbor had an average diameter of 2.075 μm (200 measured), with a standard deviation of 
0.6203 μm and a range of 0.64-5.39 μm. Particles jetted in Karlsruhe had an average diameter of 
1.96 μm (100 measured) and a standard deviation of 0.642 μm with a range of 0.9-3.7 μm. Thus 
particle size is very similar. Images of both sets of particles are seen in Fig. 12. Shape and 
surface morphology are similar, although some difference is seen due to the lack of gold sputter 
coating on the particles from Karlsruhe. During my time in Germany, the gold sputter coater was 
not working, and its caretaker was on holiday. In all, particle size and shape can be fairly closely 
reproduced on different continents, which bodes well for the potential of future industrialization 
of the jetting method to make biodegradable drug delivery vehicles commercially.  
 
Fig. 12. Particles jetted in Ann Arbor as compared to particles with the same formulation jetted 
in Germany, showing comparable size and morphology. Note, however, that the images from 
Karlsruhe are not sputter coated because sputter coater was not working while I was there. 
 
 
 
3.6 Jetting with Azithromycin 
 Azithromycin is an antibiotic more commonly used in the treatment of lung infections in 
CF patients. Particles containing Azithromycin were fabricated in order to supplement our data 
on carboxy-TEMPO, a nitroxide, which is part of a more experimental class of CF-related 
antibiotics. With jetting, optimization of jetting solution parameters such as polymer 
concentration, solvent ratio, and flow rate is always an important initial process.  
 Using a 95:5 solvent ratio with Azithromycin was attempted, since this was effective with 
carboxy-TEMPO. However, in Ann Arbor, there has been difficulty dissolving PSA in 95% 
CHCl3. PSA is very soluble in DMF but only slightly soluble in CHCl3, hence the complicated 
dissolution procedure necessary to produce PSA jetting solutions described previously. 
Dissolution of PSA in a 95:5 solvent ratio was possible in Germany, and thus the lack of 
solubility is currently a concern. Perhaps batch-to-batch differences occur in PSA purchased 
from Sigma, which is a concern. Of course, the polymer degrades over time, but even PSA from 
newly opened vacuum sealed bags has not proved soluble except in 70:30 solvents, or those with 
even higher DMF concentrations (e.g. 50:50).  
 Dissolving PSA has been possible in 95:5 solvents when TEA is used as an additive, but 
TEA causes instability in jetting unless coupled with carboxy-TEMPO. This causes jets to yield 
amorphous structures as opposed to spherical microparticles, as seen in Fig. 13. The exact 
chemical mechanism of TEA-carboxy-TEMPO co-stability is currently not known. It is probably 
that the two compounds form salts, neutralizing one another's charges and thus having a more 
limited effect on the dielectric constant of the solution. Since Azithromycin is largely non-polar 
and uncharged, it would not have the same interaction with the TEA.  
  
 
Fig. 13. Jetting with TEA in solutions that do not also contain carboxy-TEMPO yields 
amorphous structures. TEA can thus not be used as an additive to improve PSA solubility in 
particles which do not also encapsulate carboxy-TEMPO.   
 
Thus, a 50:50 chloroform: DMF solvent ratio was chosen. A 70:30 solvent ratio was also tested, 
but particles did not take on as smooth of a spherical shape. It is seen that encapsulating drug 
does not adversely affect particle size or shape, and that the 50:50 solvent ratio yields adequate 
particles for further analysis, as presented in Fig. 14. 
 
 
Fig. 14. Scanning electron images of PSA microparticles with and without Azithromycin, using a 
50:50 solvent ratio for the particles in both images.   
 
3.7 Dual Drug Loading 
  
 Particles were jetted which contain carboxy-TEMPO in one side only, Azithromycin in 
one side only, and both carboxy-TEMPO and Azithromycin in separate compartments. Confocal 
imaging was performed in order to confirm the bi-compartmental nature of the particles. Images 
are shown in Fig. 15-17: biphasicity is clearly visible. All particles were fabricated using 20% 
PSA weight/volume, 5% drug weight/weight, a solvent ratio 50:50 CHCl3: DMF, and a flow rate 
of 0.4 mL/hour. Blue dyes and green dyes were included in compartments containing 
Azithromycin and carboxy-TEMPO, respectively, and for particles with blank compartments, the 
dye for that compartment was chosen to be the opposite color (blue if the other side was green, 
and vice versa) of the other compartment. 
 
 
 
 
 
Fig. 15. Scanning Electron Microscope and Confocal Laser Scanning Microscope images of 
Particles containing carboxy-TEMPO in one side and nothing in the other.  
 
 
 
Fig. 16. Scanning Electron Microscope and Confocal Laser Scanning Microscope images of 
Particles containing Azithromycin in one side and nothing in the other.  
 
 
 
Fig. 17. Scanning Electron Microscope and Confocal Laser Scanning Microscope images of 
Particles containing carboxy-TEMPO in one side and Azithromycin in the other.  
These dual drug delivery particles will enable enhanced treatment for drug resistant bacteria, 
since it is far less likely for bacteria to evolve resistance to both drugs than it is for them to 
evolve resistance to one drug only.  
 
 
3.8 Future Work 
 
 Future work will include solid state IR with PSA particles, both shortly after jetting and 
after being stored for different lengths of time, to determine if the polymer is degrading during 
jetting and/or storage. Other ideas will be brainstormed as well to determine whether the variable 
degradation of the polymer prior to release studies is effecting the release rate of drug from the 
particles in an uncontrollable way. Release studies will be performed with particles containing 
only carboxy-TEMPO, only Azithromycin, and both carboxy-TEMPO and Azithromycin, in 
order to compare release profiles and to determine if the bi-compartmental particles yield 
different release rates for the two drugs. Dynamic Light Scattering and Nanosight nanoparticle 
tracking analysis will be used to further quantify particle size distributions. 
 Future work with successfully fabricated particles, whose characteristics are seen as 
appropriate for CF drug delivery, will include cell toxicity testing and animal testing. A cell line 
has been identified as a promising candidate for cell studies. MucilAir is a commercially 
available in vitro, 3D model of the human epithelium sold by Epithelix in Switzerland. It is fully 
differentiated and has a shelf life of up to one year, but requires continuous surveillance because 
its media must be changed every two to three days. MucilAir mimics the in vivo tissue of the 
human respiratory epithelium by including features such as basal, goblet, ciliated cells, and 
mucus; cilia beating; metabolic activity; tight junctions; and active ion transport. MucilAir 
promises very high batch to batch reproducibility, so that multiple experiments can be performed 
without concern of error introduced by batch to batch inconsistencies. MucilAir sends cells in 
24-well plate inserts, which can easily be transferred between well plates if needed. Each insert 
is about $100, depending on the pathology, and MucilAir will send three inserts for free as a 
sample. Available for purchase are cells taken from healthy patients or patients with a variety of 
diseases, including CF, COPD, Asthma, Allergic Rhinitis, and Smoker. Epithelix ships 
worldwide, and constantly has cells ready so that they can ship within days.  
 A caveat of using MucilAir is that one must purchase their media directly from 
Switzerland, because they refuse to share exactly what makes up their media for commercial 
reasons. I personally emailed them and they said they could not disclose this information, which 
is frustrating as a scientist who wishes to know exactly what they are feeding to their cells. In the 
end, the pros of using MucilAir seem to outweigh the cons, and I would advise that future in 
vitro studies be done using this model. Interfacing with Epithelix via email tends to yield a 
response within 3 days, so samples can be sent quickly and experiments may be done in an 
efficient manner. 
 After cell toxicity testing, in vivo studies will be performed. CF in vivo work is generally 
done using either mice or pigs as models. The eventual goal is to put these particles into clinical 
trials, and to eventually use them to better treat CF disease. 
 Overall, it is important to develop CF-optimized microparticles with highly specific drug 
delivery benefits in order to heal tens of thousands of patients worldwide. Moreover, the 
methodology developed from my research also will have potential uses for applications to other 
disease treatments. 
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